Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dapoxetine/Sildenafil Combination for PE and ED
NCT02939495Phase 4Completed
- Sponsor
- Neutec Group
- Start
- Oct 2016
- Primary completion
- Jun 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of dapoxetine and ASP-001 in premature ejaculation (PE) and erectile dysfunction (ED), sponsored by Neutec Group. Primary endpoints: Intra-vaginal Ejaculation Latency Time at 4 weeks, International Index of Erectile Function Questionnaire at 4 weeks and 1 more. Started Oct 2016; status: completed.
02
Drugs
dapoxetineASP-001
03
Conditions
premature ejaculation (PE)erectile dysfunction (ED)
Beyond the preview
Go deeper on NCT02939495.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02939495.